Literature DB >> 16988848

[Comorbidity in rheumatoid arthritis of early onset. Effects on outcome parameters].

G Westhoff1, C Weber, A Zink.   

Abstract

Three-year follow-up data of 1,032 patients with recent onset rheumatoid arthritis (RA) were analyzed regarding the frequency of 21 common comorbid chronic conditions and their impact on health outcome (i.e., pain, functional capacity, disease activity, and radiographic joint damage). Multivariate logistic regression analyses were used to calculate age- and gender-adjusted odds ratios for each chronic condition on severe functional capacity (<60% of full function). Comorbidity was already common at the onset of RA, with 72% of the patients having at least one comorbid condition and almost 50% having at least two. Common comorbidities were associated with significantly worse baseline measures in at least three of seven investigated outcome parameters. The more of these conditions patients had, the worse their 3-year outcome. Functional capacity was most sensitive to comorbid conditions. In logistic regression, obesity, hypercholesterolemia, type II diabetes, and osteoporosis resulted in a twofold risk of severe functional limitation (<60% of full function), independent of each other and of age and gender. The impact of comorbidity on measures of disease severity should be considered when used to compare outcome parameters of different RA samples.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16988848     DOI: 10.1007/s00393-006-0102-z

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  25 in total

1.  Loss of physical independence in rheumatoid arthritis: interview data from a representative sample of patients in rheumatologic care.

Authors:  G Westhoff; J Listing; A Zink
Journal:  Arthritis Care Res       Date:  2000-02

Review 2.  Relative risk of cardiovascular events in patients with rheumatoid arthritis.

Authors:  Anthony N DeMaria
Journal:  Am J Cardiol       Date:  2002-03-21       Impact factor: 2.778

Review 3.  Coronary artery disease and rheumatoid arthritis.

Authors:  Nicola Goodson
Journal:  Curr Opin Rheumatol       Date:  2002-03       Impact factor: 5.006

4.  Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study.

Authors:  E J Kroot; A M van Gestel; H L Swinkels; M M Albers; L B van de Putte; P L van Riel
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database.

Authors:  Douglas J Watson; Thomas Rhodes; Harry A Guess
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

Review 7.  Inter-relationships between rheumatoid arthritis and periodontal disease. A review.

Authors:  F B Mercado; R I Marshall; P M Bartold
Journal:  J Clin Periodontol       Date:  2003-09       Impact factor: 8.728

8.  Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity.

Authors:  Gregorio Navarro-Cano; Inmaculada Del Rincón; Samvel Pogosian; José F Roldán; Agustín Escalante
Journal:  Arthritis Rheum       Date:  2003-09

9.  Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis.

Authors:  Frederick Wolfe; Bruce Freundlich; Walter L Straus
Journal:  J Rheumatol       Date:  2003-01       Impact factor: 4.666

10.  Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation.

Authors:  Caroline Jochems; Ulrika Islander; Malin Erlandsson; Margareta Verdrengh; Claes Ohlsson; Hans Carlsten
Journal:  Arthritis Res Ther       Date:  2005-04-27       Impact factor: 5.156

View more
  9 in total

1.  [Orthopedic rheumatology].

Authors:  S Rehart; M Henniger
Journal:  Orthopade       Date:  2012-07       Impact factor: 1.087

2.  [The other opinion: nephrotoxicity of low-dose methotrexate - a problem which does not exist].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2011-12       Impact factor: 1.372

Review 3.  [Safety of antirheumatic drug treatment in the elderly].

Authors:  K Krüger; A Strangfeld; C Kneitz
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

4.  [Prevalence, comorbidity and interdisciplinary treatment of rheumatoid arthritis - Insurance data on outpatient and inpatient care in Baden-Württemberg].

Authors:  A Strahl; O Schneider; J Frankenhauser-Mannuß; S Knapstein; C Hermann; B Lembeck; H-M Lorenz; W Rüther; J Flechtenmacher
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

5.  [Managing comorbidities of inflammatory rheumatic diseases].

Authors:  K de Groot; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

6.  [Is the treatment response in elderly patients with rheumatoid arthritis diminished? Results of a prospective study over 3 months].

Authors:  C Fiehn; S Kessler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

7.  [Which kind of structures and facilities are needed for the care of elderly patients with rheumatic diseases?].

Authors:  C Fiehn
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

8.  [Multimorbidity in elderly rheumatic patients part 1].

Authors:  H-J Lakomek; T Brabant; M Lakomek; D Lüttje
Journal:  Z Rheumatol       Date:  2013-08       Impact factor: 1.372

9.  Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.

Authors:  Veena K Ranganath; Paul Maranian; David A Elashoff; Thasia Woodworth; Dinesh Khanna; Theodore Hahn; Catherine Sarkisian; Joel M Kremer; Daniel E Furst; Harold E Paulus
Journal:  Rheumatology (Oxford)       Date:  2013-06-27       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.